{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T15:21:05Z","timestamp":1773156065617,"version":"3.50.1"},"reference-count":20,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Changes in the immunoglobulin G1 (IgG1)\/IgG2 ratio following vaccination can indicate the activation of cellular control mechanisms typical of a T-cell-dependent response. We examined IgG subclass ratios in 17 healthy adults (26 to 55 years of age) before and 4 to 6 weeks following immunization with a quadrivalent meningococcal-polysaccharide diphtheria toxoid conjugate vaccine against serogroups A, C, Y, and W135. Serologic responses were determined by serum bactericidal antibody assay and serogroup-specific IgG, IgG1, and IgG2 enzyme-linked immunosorbent assay. Prevaccination serogroup A-specific IgG1\/IgG2 ratios were &lt;1 for all subjects and differed by subject for C, Y, and W-135. Postvaccination, significant increases in IgG, IgG1, and IgG2, were observed for all serogroups. Serogroup-specific IgG1\/IgG2 ratios increased for group A (14\/17 subjects, 88%), decreased in more than half of subjects for groups C (9\/17, 53%) and W135 (12\/17, 71%) and decreased for serogroup Y (16\/17, 94%). IgG1\/IgG2 ratios differed between individual vaccinees and were similar to the responses of adults who received pneumococcal conjugate vaccines or a monovalent C conjugate vaccine. Further studies on IgG subclasses following meningococcal polysaccharide and conjugate vaccination are needed.<\/jats:p>","DOI":"10.1128\/cvi.13.4.507-510.2006","type":"journal-article","created":{"date-parts":[[2006,4,7]],"date-time":"2006-04-07T15:13:26Z","timestamp":1144422806000},"page":"507-510","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":25,"title":["Immunoglobulin G Subclass Response to a Meningococcal Quadrivalent Polysaccharide-Diphtheria Toxoid Conjugate Vaccine"],"prefix":"10.1128","volume":"13","author":[{"given":"Helen","family":"Findlow","sequence":"first","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, P.O. Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, United Kingdom"},{"name":"Department of Pathology and Microbiology, University of Bristol, Bristol, United Kingdom"},{"name":"Immunisation Department, HPA Centre for Infections, Collindale, London, United Kingdom"},{"name":"Gloucester Vaccine Evaluation Unit, Gloucester HPA, Gloucester, United Kingdom"},{"name":"Bristol HPA Laboratory, Bristol, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Southern","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, P.O. Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, United Kingdom"},{"name":"Department of Pathology and Microbiology, University of Bristol, Bristol, United Kingdom"},{"name":"Immunisation Department, HPA Centre for Infections, Collindale, London, United Kingdom"},{"name":"Gloucester Vaccine Evaluation Unit, Gloucester HPA, Gloucester, United Kingdom"},{"name":"Bristol HPA Laboratory, Bristol, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Mabey","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, P.O. Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, United Kingdom"},{"name":"Department of Pathology and Microbiology, University of Bristol, Bristol, United Kingdom"},{"name":"Immunisation Department, HPA Centre for Infections, Collindale, London, United Kingdom"},{"name":"Gloucester Vaccine Evaluation Unit, Gloucester HPA, Gloucester, United Kingdom"},{"name":"Bristol HPA Laboratory, Bristol, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Balmer","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, P.O. Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, United Kingdom"},{"name":"Department of Pathology and Microbiology, University of Bristol, Bristol, United Kingdom"},{"name":"Immunisation Department, HPA Centre for Infections, Collindale, London, United Kingdom"},{"name":"Gloucester Vaccine Evaluation Unit, Gloucester HPA, Gloucester, United Kingdom"},{"name":"Bristol HPA Laboratory, Bristol, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Heyderman","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, P.O. Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, United Kingdom"},{"name":"Department of Pathology and Microbiology, University of Bristol, Bristol, United Kingdom"},{"name":"Immunisation Department, HPA Centre for Infections, Collindale, London, United Kingdom"},{"name":"Gloucester Vaccine Evaluation Unit, Gloucester HPA, Gloucester, United Kingdom"},{"name":"Bristol HPA Laboratory, Bristol, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cressida","family":"Auckland","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, P.O. Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, United Kingdom"},{"name":"Department of Pathology and Microbiology, University of Bristol, Bristol, United Kingdom"},{"name":"Immunisation Department, HPA Centre for Infections, Collindale, London, United Kingdom"},{"name":"Gloucester Vaccine Evaluation Unit, Gloucester HPA, Gloucester, United Kingdom"},{"name":"Bristol HPA Laboratory, Bristol, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhonwen","family":"Morris","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, P.O. Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, United Kingdom"},{"name":"Department of Pathology and Microbiology, University of Bristol, Bristol, United Kingdom"},{"name":"Immunisation Department, HPA Centre for Infections, Collindale, London, United Kingdom"},{"name":"Gloucester Vaccine Evaluation Unit, Gloucester HPA, Gloucester, United Kingdom"},{"name":"Bristol HPA Laboratory, Bristol, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Miller","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, P.O. Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, United Kingdom"},{"name":"Department of Pathology and Microbiology, University of Bristol, Bristol, United Kingdom"},{"name":"Immunisation Department, HPA Centre for Infections, Collindale, London, United Kingdom"},{"name":"Gloucester Vaccine Evaluation Unit, Gloucester HPA, Gloucester, United Kingdom"},{"name":"Bristol HPA Laboratory, Bristol, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, P.O. Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, United Kingdom"},{"name":"Department of Pathology and Microbiology, University of Bristol, Bristol, United Kingdom"},{"name":"Immunisation Department, HPA Centre for Infections, Collindale, London, United Kingdom"},{"name":"Gloucester Vaccine Evaluation Unit, Gloucester HPA, Gloucester, United Kingdom"},{"name":"Bristol HPA Laboratory, Bristol, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"780","volume":"10","year":"2003","unstructured":"Andrews, N., R. Borrow, and E. Miller. 2003. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol.10:780-786.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_3_2","first-page":"1","volume":"54","year":"2005","unstructured":"Bilukha, O. O., and N. E. Rosenstein. 2005. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly. Rep.54:1-21.","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.3.1568-1573.2001"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1086\/345763","volume":"186","year":"2002","unstructured":"Campbell, J. D., R. Edelman, J. C. King, Jr., T. Papa, R. Ryall, and M. B. Rennels. 2002. Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults. J. Infect. Dis.186:1848-1851.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.30.1.154-159.1992"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1086\/338474","volume":"185","year":"2002","unstructured":"Goldblatt, D., R. Borrow, and E. Miller. 2002. Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults. J. Infect. Dis.185:397-400.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.2.2.132-137.1995"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.12.8256-8265.2005"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1056\/NEJM198608213150807","volume":"315","year":"1986","unstructured":"Insel, R. A., and P. W. Anderson. 1986. Response to oligosaccharide-protein conjugate vaccine against Haemophilus influenzae b in two patients with IgG2 deficiency unresponsive to capsular polysaccharide vaccine. N. Engl. J. Med.315:499-503.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CDLI.11.1.1-5.2004","volume":"11","year":"2004","unstructured":"Joseph, H., P. Balmer, M. Bybel, T. Papa, R. Ryall, and R. Borrow. 2004. Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera. Clin. Diagn. Lab. Immunol.11:1-5.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/archpedi.159.10.907","volume":"159","year":"2005","unstructured":"Keyserling, H., T. Papa, K. Koranyi, R. Ryall, E. Bassily, M. J. Bybel, K. Sullivan, G. Gilmet, and A. Reinhardt. 2005. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch. Pediatr. Adolesc. Med.159:907-913.","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.9.4935-4938.1999"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1086\/317667","volume":"183","year":"2001","unstructured":"Maclennan, J., S. Obaro, J. Deeks, D. Lake, C. Elie, G. Carlone, E. R. Moxon, and B. Greenwood. 2001. Immunologic memory 5 years after meningococcal A\/C conjugate vaccination in infancy. J. Infect. Dis.183:97-104.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.4.2.156-167.1997"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1651-2227.1979.tb04424.x","volume":"68","year":"1979","unstructured":"Oxelius, V. A. 1979. IgG subclass levels in infancy and childhood. Acta Paediatr. Scand.68:23-27.","journal-title":"Acta Paediatr. Scand."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.inf.0000148928.10057.86","volume":"24","year":"2005","unstructured":"Pichichero, M., J. Casey, M. Blatter, E. Rothstein, R. Ryall, M. Bybel, G. Gilmet, and T. Papa. 2005. A comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two ten-year-old children. Pediatr. Infect. Dis. J.24:57-62.","journal-title":"Pediatr. Infect. Dis. J."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.4049\/jimmunol.137.8.2670","volume":"137","year":"1986","unstructured":"Rautonen, N., J. Pelkonen, S. Sipinen, H. Kayhty, and O. Makela. 1986. Isotype concentrations of human antibodies to group A meningococcal polysaccharide. J. Immunol.137:2670-2675.","journal-title":"J. Immunol."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.6.5.651-656.1972"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1128\/CDLI.12.1.218-223.2005","volume":"12","year":"2005","unstructured":"Sikkema, D. J., N. A. Ziembiec, T. R. Jones, S. W. Hildreth, D. V. Madore, and S. A. Quataert. 2005. Assignment of weight-based immunoglobulin G1 (IgG1) and IgG2 units in antipneumococcal reference serum lot 89-S(F) for pneumococcal polysaccharide serotypes 1, 4, 5, 7F, 9V, and 18C. Clin. Diagn. Lab. Immunol.12:218-223.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/S0264-410X(98)00475-7","volume":"17","year":"1999","unstructured":"Soininen, A., I. Seppala, T. Nieminen, J. Eskola, and H. Kayhty. 1999. IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines. Vaccine17:1889-1897.","journal-title":"Vaccine"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.13.4.507-510.2006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.13.4.507-510.2006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T23:48:03Z","timestamp":1683416883000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.13.4.507-510.2006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["10.1128\/CVI.13.4.507-510.2006"],"URL":"https:\/\/doi.org\/10.1128\/cvi.13.4.507-510.2006","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4]]},"assertion":[{"value":"2005-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2006-02-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}